Trials / Completed
CompletedNCT02811497
Study of Azacitidine and Durvalumab in Advanced Solid Tumors
An Open-label, Phase II Basket Study of a hypoMEThylating Agent Oral Azacitidine and DURvalumab (MEDI4736) (Anti-PDL1) in Advanced Solid Tumors (METADUR)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 study of investigational drug, durvalumab given in combination with azacitidine (CC-486). The main purpose of this phase 2 study is to assess the antitumor activity of azacitidine in combination with durvalumab patients with microsatellite stable colorectal carcinoma (MSS-CRC), platinum resistant epithelial ovarian cancer type II (PR-OC), and estrogen receptor positive and HER2 negative breast cancer.
Conditions
- Microsatellite Stable Colorectal Carcinoma
- Platinum Resistant Epithelial Ovarian Cancer Type II
- Estrogen Receptor Positive and HER2 Negative Breast Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azacitidine | |
| DRUG | Durvalumab |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2018-11-08
- Completion
- 2020-08-04
- First posted
- 2016-06-23
- Last updated
- 2021-04-01
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02811497. Inclusion in this directory is not an endorsement.